CoChat
Sign Up
Cited by 471Autism Spectrum Disorder ResearchCircadian rhythm and melatoninSleep and related disorders

The DOI matches its Crossref record.

Melatonin in autism spectrum disorders: a systematic review and meta-analysis

Open access
ROSSIGNOL, DANIEL A, FRYE, RICHARD E·2011·Developmental Medicine & Child Neurology
DOI 10.1111/j.1469-8749.2011.03980.x
Open this paper in CoChat — free accountOpen PDF

Abstract

AIM: The aim of this study was to investigate melatonin-related findings in autism spectrum disorders (ASD), including autistic disorder, Asperger syndrome, Rett syndrome, and pervasive developmental disorders, not otherwise specified. METHOD: Comprehensive searches were conducted in the PubMed, Google Scholar, CINAHL, EMBASE, Scopus, and ERIC databases from their inception to October 2010. Two reviewers independently assessed 35 studies that met the inclusion criteria. Of these, meta-analysis was performed on five randomized double-blind, placebo-controlled studies, and the quality of these trials was assessed using the Downs and Black checklist. RESULTS: Nine studies measured melatonin or melatonin metabolites in ASD and all reported at least one abnormality, including an abnormal melatonin circadian rhythm in four studies, below average physiological levels of melatonin and/or melatonin derivates in seven studies, and a positive correlation between these levels and autistic behaviors in four studies. Five studies reported gene abnormalities that could contribute to decreased melatonin production or adversely affect melatonin receptor function in a small percentage of children with ASD. Six studies reported improved daytime behavior with melatonin use. Eighteen studies on melatonin treatment in ASD were identified; these studies reported improvements in sleep duration, sleep onset latency, and night-time awakenings. Five of these studies were randomized double-blind, placebo-controlled crossover studies; two of the studies contained blended samples of children with ASD and other developmental disorders, but only data for children with ASD were used in the meta-analysis. The meta-analysis found significant improvements with large effect sizes in sleep duration (73 min compared with baseline, Hedge's g 1.97 [95% confidence interval {CI} CI 1.10-2.84], Glass's Δ 1.54 [95% CI 0.64-2.44]; 44 min compared with placebo, Hedge's g 1.07 [95% CI 0.49-1.65], Glass's Δ 0.93 [95% CI 0.33-1.53]) and sleep onset latency (66 min compared with baseline, Hedge's g-2.42 [95% CI -1.67 to -3.17], Glass's Δ-2.18 [95% CI -1.58 to -2.76]; 39 min compared with placebo, Hedge's g-2.46 [95% CI -1.96 to -2.98], Glass's Δ-1.28 [95% CI -0.67 to -1.89]) but not in night-time awakenings. The effect size varied significantly across studies but funnel plots did not indicate publication bias. The reported side effects of melatonin were minimal to none. Some studies were affected by limitations, including small sample sizes and variability in the protocols that measured changes in sleep parameters. INTERPRETATION: Melatonin administration in ASD is associated with improved sleep parameters, better daytime behavior, and minimal side effects. Additional studies of melatonin would be helpful to confirm and expand on these findings.

Overview

Integrity signals

Registry

Crossref · 10.1111/j.1469-8749.2011.03980.x

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cited by

Sorted by citations

Items 301–400 of 471

Related

See all

Metadata

Authors
ROSSIGNOL, D. A., & FRYE, R. E.
Affiliations
The University of Texas Health Science Center at Houston (US)
Corresponding author
ROSSIGNOL, DANIEL A
ORCID
Venue
Developmental Medicine & Child Neurology
Publisher
Wiley
Published
2011-04-19
Volume
53
Issue
9
Pages
783-792
ISSN
  • 0012-1622 (ISSN-L)
  • 1469-8749
DOI
10.1111/j.1469-8749.2011.03980.x
OpenAlex
W2045069726
Cited by
468
References
0
Citations by year
2026: 16 · 2025: 32 · 2024: 28 · 2023: 39 · 2022: 49 · 2021: 32 · 2020: 43 · 2019: 31 · 2018: 27 · 2017: 28 · 2016: 31 · 2015: 30 · 2014: 36 · 2013: 26 · 2012: 12
FWCI
13.15
Type
journal article
Language
en
Open access
Licence
onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations
  • Developmental Medicine & Child Neurology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Circadian rhythm and melatonin
  • Social Sciences › Psychology › Experimental and Cognitive Psychology › Sleep and related disorders
Keywords
melatonin, autism spectrum disorder, sleep disorders, sleep duration, sleep latency, nocturnal awakenings, melatonin metabolites, melatonin treatment
MeSH terms
Child, Child Development Disorders, Pervasive, Child, Preschool, Double-Blind Method, Humans, Melatonin, Randomized Controlled Trials as Topic, Databases, Factual

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review